Jingjiang Yong'an Pharmaceutical Co., Ltd. 2025 Annual Report Summary Securities Code: 002365 Securities Abbreviation: Yong'an Pharmaceutical Announcement No.: 2026-17 Jingjiang Yong'an Pharmaceutical Co., Ltd. 2025 Annual Report Summary
I. Important Notice This annual report summary is derived from the full annual report. To fully understand the company's operating results, financial status, and future development plans, investors should carefully read the full annual report on the designated media of the China Securities Regulatory Commission. All directors attended the board meeting to review this report. Non-standard Audit Opinion Notice □ Applicable Not Applicable Board of Directors' Review of Profit Distribution Proposal or Capital Reserve Transfer to Share Capital for the Reporting Period ☑ Applicable Not Applicable Is Capital Reserve Transferred to Share Capital? □ Yes No The profit distribution proposal reviewed and approved by the Board of Directors is as follows: Based on the current total share capital of 294,682,500 shares, deducting the 5,537,350 shares in the treasury stock account, the remaining share capital of 289,145,150 shares will be used as the base. A cash dividend of RMB 1 (tax inclusive) will be distributed per 10 shares to all shareholders. No bonus shares will be issued. Capital reserve will not be transferred to share capital. Board Resolution on Profit Distribution for Preferred Shares in the Reporting Period □ Applicable Not Applicable
II. Company Basic Information
- Company Profile Stock Abbreviation: Yong'an Pharmaceutical Stock Code: 002365 Stock Exchange: Shenzhen Stock Exchange Contacts and Contact Information Name Office Address Fax Telephone Email Board Secretary Xiong Shengjie No. 2 Guangze Avenue, Economic Development Zone, Qianjiang City, Hubei Province 0728-6202797 0728-6204039 tzz@chinataurine.com Securities Affairs Representative Zhao Xiuli No. 2 Guangze Avenue, Economic Development Zone, Qianjiang City, Hubei Province 0728-6202797 0728-6204039 tzz@chinataurine.com